米索前列醇直肠给药联合缩宫素预防产后出血临床疗效观察

Clinical efficacy observation of Misoprostol by rectal administration combinded with Oxytocin on prevention of postpartum hemorrhage

目的观察米索前列醇直肠给药联合缩宫素预防产后出血的临床疗效,探讨其临床应用价值。方法选取2010年1月～2011年8月于本院住院并足月妊娠且有产后出血高危因素的产妇98例,随机分为对照组与治疗组,每组各49例,对照组在胎儿娩出后第三产程早期给予缩宫素,观察组在对照组基础上给予米索前列醇直肠给药。观察并比较两组产妇产后出血量和产后出血发生率。结果观察组患者产后出血量为(170.32±13.32)mL,明显少于对照组的(289.47±14.14)mL,观察组第三产程时间为(6.11±0.54)min,明显少于对照组的(10.24±0.61)min,且两组患者产后出血发生率观察组小于对照组(分别为2.04%和12.24%),两者比较差异均具有统计学意义(P<0.05)。结论米索前列醇直肠给药联合缩宫素预防产后出血疗效显著,不良反应少,值得临床进一步推广和应用。

Objective To explore the clinical effect of Misoprostol by rectal administration combinded with Oxytocin on prevention of postpartum hemorrhage and its clinical value. Methods From January 2010 to August 2011 in our hospital, 98 cases of full-term pregnancy with postpartum hemorrhage risk factors were selected and randomly divided into control group and treatment group, 49 patients in each group, the control group was given early Oxytocin in the third stage of labor, the treatment group was given Misoprostol by rectal administration on the basis of the control group. The postpartum hemorrhage amount and postpartum hemorrhage incidence of two groups were compared and analyzed. Results The postpartum hemorrhage amount of treatment group was （170.32 ± 13.32） mL, which was significantly less than （289.47 ± 14.14） mL of the control group, the third stage of labor time of the observation group was （6.11 ± 0.54） min, which was significantly less than （10.24 ± 0.61） min of the control group, and the postpartum hemorrhage incidence of treatment group was lower than the control group （2.04% vs 12.24%）, the difference was significant between two groups （P 0.05）. Conclusion Carboprost Merhylate Suppositroies combinded with Oxytocin is a safe and effective method for prevention of postpartum hemorrhage, it is worth for further clinical promotion and application.